oasis 1 oral semaglutide 50 mg nejm 2023 obesity taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial For patients with #obesity, semaglutide,

"Glutathione peroxidase-1 but not -4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells"

What the clinical data shows on belly fat Controlled trials have demonstrated reductions of 15 to 20% in visceral adipose tissue over 26 weeks of treatment

Glass bottom dishes were used for cell culture due to confocal scanning requirements

My colleague T.J

Obesity is a major risk factor for high blood pressure, so by promoting weight loss, semaglutide often leads to a meaningful drop in blood pressure, including for people whose readings remain high despite taking blood pressure medications

CagriSema expected approval ~2026 if trials succeed